Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
IPO Year:
Exchange: NYSE
Website: bd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $255.00 → $275.00 | Neutral → Buy | Citigroup |
| 5/30/2024 | $274.00 | Buy | Goldman |
| 7/24/2023 | $305.00 | Mkt Perform → Outperform | Raymond James |
| 5/30/2023 | $295.00 | Overweight | Morgan Stanley |
| 5/5/2023 | $260.00 → $290.00 | Neutral → Overweight | Piper Sandler |
| 4/12/2023 | $304.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 1/3/2023 | $250.00 → $290.00 | Neutral → Buy | BofA Securities |
| 12/12/2022 | $221.00 → $250.00 | Sell → Neutral | Citigroup |
| 7/11/2022 | $265.00 → $235.00 | Neutral → Sell | Citigroup |
| 6/24/2022 | $275.00 | Equal Weight → Overweight | Wells Fargo |
The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
- Reuters
Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:BDX). The medical technology company, which supplies approximately 8 billion syringes and needle pens annually across more than 100 countries, has engaged advisers from Centerview Partners to explore a sale. Embecta’s share price has plummeted nearly 70% since its April 2022 spin-off, leaving the Nasdaq-listed firm valued at $2.1 billion. The decline is attributed to several factors, including the impact of GLP-1 drugs such as Novo Nord
Becton Dickinson's (NYSE:BDX) short percent of float has risen 17.65% since its last report. The company recently reported that it has 2.32 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.55 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
Jim Lebenthal of Cerity Partners hyped UnitedHealth Group Incorporated (NYSE:UNH) as a “solid” healthcare company in the latest edition of CNBC's “Halftime Report Final Trades.” On July 9, Cantor Fitzgerald analyst Sarah James reiterated UnitedHealth with an Overweight rating and maintained a price target of $591. Don't forget to check out our premarket coverage here. Brian Belski of BMO Capital Markets said First Citizens BancShares, Inc. (NASDAQ:FCNCA) is a “great, great brand.” First Citizens BancShares is expected to report its financial results for the quarter ended June 30, 2024, before the opening bell on Thursday, July 25. Analysts expect the company to report quarterly
Citigroup analyst Joanna Wiensch maintains Becton Dickinson (NYSE:BDX) with a Neutral and lowers the price target from $260 to $255.
- Reuters
This furthers the company's progress toward its goal to reach net zero GHG emissions across its value chain by FY 2050
Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:BDX) with a Outperform and lowers the price target from $290 to $285.
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
3 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa
For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
10-Q - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
CERT - BECTON DICKINSON & CO (0000010795) (Filer)
8-A12B - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
FWP - BECTON DICKINSON & CO (0000010795) (Subject)
BROWNSVILLE, Texas, Nov. 20, 2024 /PRNewswire/ -- A first of its kind Human Papillomavirus (HPV) self-collection screening pilot program aimed at improving cervical cancer screening in underserved communities has officially launched in Texas. HPV is the cause of virtually all cervical cancers. The study is being conducted at Su Clinica, a Federally Qualified Health Center (FQHC) with locations in Brownsville, Harlingen, Raymondville, and Santa Rosa, Texas, together with researchers at The University of Texas MD Anderson Cancer Center. This study will evaluate the implementatio
FRANKLIN LAKES, N.J., Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:50 am Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports t
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organicQ4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectivelyFY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organicFY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectivelyFY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
FRANKLIN LAKES, N.J., Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.04 per common share, an increase of 9.5% from the previous quarter. The dividend will be payable on December 31, 2024 to holders of record on December 9, 2024. The indicated annual dividend rate for fiscal year 2025 is $4.16 per share. "This is the 53rd consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc
FRANKLIN LAKES, N.J., Oct. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today launched the new BD® Intraosseous Vascular Access System, enabling access for rapid delivery of fluids or medication in critical emergency situations. The procedure involves inserting a needle into the bone marrow cavity when intravenous (IV) access is challenging or delayed. The BD® IO System can quickly provide access to the circulatory system for adult and pediatric patients and is built for rapid intervention in varied emerge
MISSISSAUGA, ON, Oct. 29, 2024 /CNW/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today Health Canada approval of the BD Onclarity™ HPV Assay for human papillomavirus (HPV) testing for the use with self-collected vaginal specimens at home. Self-collected samples provide an alternative to the traditional Pap test performed by a clinician with a speculum, making cervical cancer screening more accessible. Compared to the traditional Pap test, HPV self-collection is less invasive, more cost-effective, and requires less
FRANKLIN LAKES, N.J., Oct. 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has been named as one of the 100 Best Corporate Citizens of 2024 by 3BL, ranking second in the health care equipment and services industry for its second consecutive year. The 100 Best Corporate Citizens list recognizes outstanding environmental, social and governance transparency and performance among 1,000 of the largest U.S. public companies. Rankings are based on over 200 factors across seven pillars – including
Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing FRANKLIN LAKES, N.J., Oct. 14, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits that will enable automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies. The automated solution from the BD and Hamilton
Announces Dates for Fiscal 2025 Quarterly Earnings Webcasts FRANKLIN LAKES, N.J., Oct. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will report financial results for its fiscal 2024 fourth quarter and full year on Thursday, Nov. 7, 2024. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news release and presentation materials will include summary financial information for the company's fiscal 2024 fourth quarter and full year, which ended on Sept. 30, 2024. BD management will hos
No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases.Settlement amount within current product litigation reserve and will be paid out over a multi-year period.Settlement will not change BD's cash flow goals or capital allocation strategy.FRANKLIN LAKES, N.J., Oct. 2, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has reached an agreement to resolve the vast majority of its existing hernia litigation. Terms of the
Citigroup upgraded Becton Dickinson from Neutral to Buy and set a new price target of $275.00 from $255.00 previously
Goldman initiated coverage of Becton Dickinson with a rating of Buy and set a new price target of $274.00
Raymond James upgraded Becton Dickinson from Mkt Perform to Outperform and set a new price target of $305.00
Morgan Stanley resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $295.00
Piper Sandler upgraded Becton Dickinson from Neutral to Overweight and set a new price target of $290.00 from $260.00 previously
KeyBanc Capital Markets upgraded Becton Dickinson from Sector Weight to Overweight and set a new price target of $304.00
BofA Securities upgraded Becton Dickinson from Neutral to Buy and set a new price target of $290.00 from $250.00 previously
Citigroup upgraded Becton Dickinson from Sell to Neutral and set a new price target of $250.00 from $221.00 previously
Citigroup downgraded Becton Dickinson from Neutral to Sell and set a new price target of $235.00 from $265.00 previously
Wells Fargo upgraded Becton Dickinson from Equal Weight to Overweight and set a new price target of $275.00
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /PRNewswire/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio
Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD ((Becton, Dickinson and Company, NYSE:BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Steve Schwartz, Azenta President and Chief
FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors. Waldstreicher, 63, was most recently the chief medical officer for Johnson & Johnson (J&J), serving in this capacity from 2012 until her retirement in 2023. As chief medical officer, she provided visionary strategic and operational leadership at J&J, with global responsibility for safety, epidemiology, regulatory and clinical operations transformatio
FRANKLIN LAKES, N.J., Jan. 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently s
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022. In addition, Story will be a member of the Nominating and Corporate Governance Committee of the Board. Story joins the LivaNova Board with more than 20 years of experience in the global medical technology industry. She currently serves as Worldwide President, Integrated Diagnostic Solutions at BD (Becton, Dickinson and Company) a position she assumed in April 2021. Prior to that, she spent 15 years at Medtronic, where she held a variety of roles in finance, sales and business unit leader
Mike Garrison Named EVP and President, Medical segmentRick Byrd Named EVP and President, Interventional segmentFRANKLIN LAKES, N.J., Aug. 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive vice president (EVP) and president of the Medical segment, and Richard (Rick) Byrd has been named executive vice president (EVP) and president of the Interventional segment, both effective Sept. 6.
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors. With these appointments, the Eyenovia Board will expand to eight seats, from six currently. "I could not be more pleased to welcome Drs. Strahlman and Palanki to our Board and look forward to their immediate contributions," stated Dr. Sean Ianchulev, chief executive officer and chief medical officer of Eyenovia. "Each brings decades of medical technology, cl
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organicQ4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectivelyFY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organicFY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectivelyFY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
FRANKLIN LAKES, N.J., Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.04 per common share, an increase of 9.5% from the previous quarter. The dividend will be payable on December 31, 2024 to holders of record on December 9, 2024. The indicated annual dividend rate for fiscal year 2025 is $4.16 per share. "This is the 53rd consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc
Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision toolsCombination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilitiesBusiness renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segmentKatie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide presidentFRANKLIN LAKES, N.J., Sept. 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technolo
Strong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growthGAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectivelyYear-to-date Cash from Continuing Operations grew 60% to $2.7 billion and Free Cash Flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectivelyThe company updated its fiscal 2024 GAAP revenue growth guidance to approximately 3.7%, and its organic revenue growth guidance to 5.0% to 5.25%The company increased its fiscal 2024 adjusted diluted EPS guidance by 5 cents at the midpoint to $13.05 to $13.1
FRANKLIN LAKES, N.J., July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that he
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organicQ2 GAAP and adjusted diluted EPS of $1.85 and $3.17 grew 20.9% and 10.8%, respectivelyYear-to-date Cash from Continuing Operations of $1.4 billion and Free Cash Flow of $1.1 billion increased $785 million and over $900 million, respectivelyCompany raises full-year adjusted EPS guidance and affirms organic revenue growth guidanceFRANKLIN LAKES, N.J., May 2, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its second quarte
FRANKLIN LAKES, N.J., April 30, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on June 28, 2024 to holders of record on June 10, 2024. The indicated annual dividend rate is $3.80 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advan
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q1 revenue of $4.7 billion increased 2.6% as reported, 1.6% currency-neutral and 2.4% organicQ1 GAAP and adjusted diluted EPS from continuing operations of $0.96 and $2.68, respectivelyCompany raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidanceFRANKLIN LAKES, N.J., Feb. 1, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2024, which ended December 31, 2023. "Our Q1 results reflect our team's strong execution of our BD 2025 strategy, in particular lev
FRANKLIN LAKES, N.J., Jan. 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on March 29, 2024 to holders of record on March 8, 2024. The indicated annual dividend rate is $3.80 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advan
Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System Revenue of $4.9 billion increased 5.1% as reported and 6.3% on a currency-neutral basisRevenue from base business (which excludes COVID-only diagnostic testing) grew 6.7% as reported, 7.9% currency-neutral or 6.3% organicGAAP and adjusted diluted EPS from continuing operations of $1.36 and $2.96, respectivelyCompany raises full-year base organic revenue growth guidance; maintains full-year adjusted EPS guidanceFRANKLIN LAKES, N.J., Aug. 3, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global med